EANS-News: AGENNIX AG
Agennix AG Schedules Conference Call on November 30,
2012 to Discuss Third Quarter 2012 Financial Results
-------------------------------------------------------------------------------- Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- Company Information Planegg/Munich (Germany) and Princeton, NJ, November 6, 2012 (euro adhoc) - Agennix AG (Frankfurt Stock Exchange: AGX) today announced that the Company will hold a conference call to discuss financial results for the third quarter and first nine months of 2012 and to provide a business update. The results will be published on Friday, November 30, 2012 in advance of the conference call. Please note that this date is a change from the previously announced date of November 8, 2012. The conference call, which will be conducted in English, will be held on Friday, November 30, 2012 at 9 AM EST/3 PM CET. A live webcast will be available on the Agennix Web site at www.agennix.com. A replay will be available via the Web site following the live event. Dial-in numbers for the call are as follows: Participants from Europe: 0049 (0)69 710 445 598 0044 (0)20 3003 2666 Participants from the U.S.: 1 212 999 6659 Please dial in 10 minutes before the beginning of the call. About Agennix Agennix AG is a publicly listed biopharmaceutical company that is focused on the development of novel therapies that have the potential to substantially lengthen and improve the lives of critically ill patients in areas of major unmet medical need. The Company's clinical development programs include oral talactoferrin alfa; RGB-286638, a multi-targeted kinase inhibitor; and a topical gel form of talactoferrin. Agennix's registered seat is in Heidelberg, Germany. The Company has two sites of operation: Planegg/Munich, Germany and Princeton, New Jersey. For additional information, please visit the Agennix Web site at www.agennix.com. This press release contains forward-looking statements, which express the current beliefs and expectations of the management of Agennix AG, including statements about cash reach. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from those expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. The achievement of positive results in early stage clinical studies does not ensure that later stage clinical studies will be successful. There can be no guarantee that the Company will have or be able to obtain the financial resources to conduct additional studies with its product candidates or that it will be successful in pursuing other business opportunities. Forward-looking statements speak only as of the date on which they are made and Agennix undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future. Agennix® is a trademark of Agennix AG. Further inquiry note: Barbara Mueller Manager, Investor Relations & Corporate Communications Phone: +49 (0)89 8565 2693 ir@agennix.com In the U.S.: Laurie Doyle Senior Director, Investor Relations & Corporate Communications Phone: +1 609 524 5884 laurie.doyle@agennix.com end of announcement euro adhoc -------------------------------------------------------------------------------- company: AGENNIX AG Im Neuenheimer Feld 515 D-69120 Heidelberg phone: +49 89 8565 2693 FAX: +49 89 8565 2610 mail: ir@agennix.com WWW: http://www.agennix.com sector: Pharmaceuticals ISIN: DE000A1A6XX4 indexes: CDAX, Prime All Share, Technology All Share stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf, regulated dealing/prime standard: Frankfurt language: English
Original-Content von: AGENNIX AG i.L., übermittelt durch news aktuell